Skip to main content
SCM Lifescience Co., Ltd. logo

SCM Lifescience Co., Ltd. — Investor Relations & Filings

Ticker · 298060 ISIN · KR7298060005 KO Manufacturing
Open in API
Filings indexed 418 across all filing types
Latest filing 2020-12-15 Regulatory Filings
Country KR South Korea
Listing KO 298060

About SCM Lifescience Co., Ltd.

http://www.scmlifescience.com/en/

SCM Lifescience Co., Ltd. is a biotechnology company focused on developing high-purity, high-efficacy stem cell therapeutics for difficult-to-treat and incurable diseases. The company utilizes its proprietary source technology, the Subfractionation Culturing Method, to isolate and culture potent stem cells. Its pipeline consists of allogeneic stem cell therapies targeting immunological conditions, which are undergoing clinical trials. SCM Lifescience is also establishing mass production manufacturing processes using 3D bioreactor technology and expanding its research into induced pluripotent stem cells (iPSC) and tissue engineering. The company's business areas also include contract manufacturing (CMO), contract research, consulting, and cosmetics.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the closure of the shareholder register for the purpose of determining shareholders eligible to vote at the 7th Annual General Meeting. It is a standard corporate notice regarding administrative procedures for a meeting, not the meeting materials themselves or a financial report. Given its nature as a regulatory notification of a corporate action, it fits best under the general regulatory filings category.
2020-12-15 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides the date, time, location (online), and purpose of the meeting. Since it is an announcement of an event rather than the presentation slides themselves, and it is under 5,000 characters, it falls under the category of a Report Publication Announcement or general regulatory filing regarding corporate events.
2020-12-10 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard South Korean regulatory disclosure form (often referred to as the '10% rule' or 'insider trading report') where company executives report changes in their personal shareholdings. This falls under the category of Director's Dealing (DIRS) as it details personal share transactions by a company executive (Jung Sung-woo).
2020-12-01 Korean
분기보고서 (2020.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for SCM Lifescience Co., Ltd. covering the period from January 1, 2020, to September 30, 2020. It contains detailed financial information, business descriptions, capital changes, and management details, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-13 Korean
투자판단관련주요경영사항(스템키말 (Stemchymal, 척수소뇌성 실조증 대상 줄기세포치료제)의 국내독점 라이선스 도입 계약 체결)
M&A Activity Classification · 100% confidence The document is a regulatory filing from SCM Lifescience Co., Ltd. regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically announcing the signing of an exclusive domestic licensing agreement for a stem cell therapy (Stemchymal). This type of disclosure regarding business partnerships, licensing, and technology acquisition falls under general regulatory filings as it does not fit into specific categories like M&A (which usually implies corporate mergers/acquisitions) or capital financing updates. Given the nature of the disclosure as a standard regulatory announcement of a business event, it is classified as a Regulatory Filing (RNS).
2020-10-13 Korean
기타경영사항(자율공시)(임상 2a상 진행 중인 급성 췌장염치료제(SCM-AGH)의 국내 개발단계 희귀의약품 지정 승인)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) from SCM Lifescience regarding the approval of their acute pancreatitis treatment (SCM-AGH) as a 'development-stage orphan drug' by the Ministry of Food and Drug Safety. It does not fit into specific categories like financial reports, board changes, or dividend announcements. As it is a regulatory announcement regarding a specific corporate development that does not fall into the other defined categories, it is classified as a Regulatory Filing (RNS).
2020-10-07 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.